See more : Talbros Automotive Components Limited (TALBROAUTO.BO) Income Statement Analysis – Financial Results
Complete financial analysis of IRadimed Corporation (IRMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IRadimed Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- NRx Pharmaceuticals, Inc. (NRXP) Income Statement Analysis – Financial Results
- De.mem Limited (DEM.AX) Income Statement Analysis – Financial Results
- Samuel Heath & Sons plc (HSM.L) Income Statement Analysis – Financial Results
- Harsha Engineers International Limited (HARSHA.BO) Income Statement Analysis – Financial Results
- Hexagon Purus ASA (HPUR.OL) Income Statement Analysis – Financial Results
IRadimed Corporation (IRMD)
About IRadimed Corporation
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.56M | 53.30M | 41.81M | 31.72M | 38.52M | 30.44M | 23.08M | 32.50M | 31.59M | 15.65M | 11.34M | 7.69M |
| Cost of Revenue | 15.40M | 12.02M | 9.76M | 8.14M | 8.82M | 7.21M | 5.57M | 6.15M | 5.84M | 3.40M | 2.85M | 2.13M |
| Gross Profit | 50.16M | 41.28M | 32.05M | 23.57M | 29.70M | 23.23M | 17.51M | 26.34M | 25.75M | 12.25M | 8.49M | 5.56M |
| Gross Profit Ratio | 76.50% | 77.45% | 76.65% | 74.33% | 77.11% | 76.31% | 75.87% | 81.06% | 81.51% | 78.25% | 74.84% | 72.34% |
| Research & Development | 2.86M | 2.28M | 1.91M | 1.90M | 1.43M | 1.52M | 1.72M | 1.35M | 1.76M | 1.07M | 1.01M | 654.07K |
| General & Administrative | 15.12M | 10.70M | 9.77M | 12.27M | 10.45M | 8.71M | 9.00M | 8.80M | 7.77M | 4.82M | 2.39M | 1.55M |
| Selling & Marketing | 12.14M | 12.68M | 10.56M | 10.16M | 9.17M | 7.00M | 5.50M | 5.28M | 4.71M | 3.30M | 2.30M | 1.93M |
| SG&A | 27.26M | 23.38M | 20.33M | 22.43M | 19.62M | 15.71M | 14.50M | 14.07M | 12.48M | 8.11M | 4.69M | 3.48M |
| Other Expenses | 0.00 | 553.10K | 18.61K | 139.21K | 395.91K | 193.54K | 111.38K | 32.68K | 121.39K | -48.55K | -3.46K | 7.42K |
| Operating Expenses | 30.12M | 25.65M | 22.23M | 24.33M | 21.05M | 17.22M | 16.23M | 15.42M | 14.24M | 9.18M | 5.70M | 4.13M |
| Cost & Expenses | 45.53M | 37.68M | 32.00M | 32.47M | 29.87M | 24.44M | 21.80M | 21.58M | 20.08M | 12.59M | 8.55M | 6.26M |
| Interest Income | 1.86M | 581.85K | 34.81K | 132.19K | 388.80K | 238.11K | 122.58K | 126.42K | 148.91K | 5.70K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 581.85K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 765.18K | 670.67K | 634.01K | 603.60K | 591.18K | 559.73K | 445.27K | 248.30K | 223.94K | 149.06K | 139.04K | 106.28K |
| EBITDA | 20.80M | 16.30M | 11.22M | 582.73K | 9.89M | 7.11M | 2.59M | 11.17M | 11.51M | 3.21M | 2.93M | 1.53M |
| EBITDA Ratio | 31.73% | 29.32% | 26.84% | 1.84% | 25.68% | 23.35% | 11.24% | 34.37% | 37.15% | 20.54% | 25.80% | 19.92% |
| Operating Income | 20.04M | 15.63M | 9.82M | -756.09K | 8.65M | 6.00M | 1.29M | 10.92M | 11.51M | 3.07M | 2.79M | 1.42M |
| Operating Income Ratio | 30.56% | 29.32% | 23.48% | -2.38% | 22.45% | 19.72% | 5.57% | 33.60% | 36.44% | 19.59% | 24.58% | 18.54% |
| Total Other Income/Expenses | 1.70M | 553.10K | 18.61K | 139.21K | 395.91K | 193.54K | 111.38K | 32.68K | 121.39K | -48.55K | -3.46K | 7.42K |
| Income Before Tax | 21.74M | 16.18M | 9.84M | -616.88K | 9.04M | 6.20M | 1.40M | 10.95M | 11.63M | 3.02M | 2.78M | 1.43M |
| Income Before Tax Ratio | 33.16% | 30.36% | 23.52% | -1.94% | 23.48% | 20.36% | 6.05% | 33.70% | 36.83% | 19.28% | 24.55% | 18.63% |
| Income Tax Expense | 4.55M | 3.35M | 510.82K | -1.99M | -587.64K | -106.14K | 896.62K | 3.74M | 4.10M | 966.98K | 846.88K | 465.98K |
| Net Income | 17.19M | 12.83M | 9.33M | 1.37M | 9.63M | 6.30M | 499.76K | 7.21M | 7.53M | 2.05M | 1.94M | 966.09K |
| Net Income Ratio | 26.22% | 24.07% | 22.30% | 4.32% | 25.00% | 20.71% | 2.17% | 22.20% | 23.83% | 13.10% | 17.08% | 12.57% |
| EPS | 1.36 | 1.02 | 0.76 | 0.11 | 0.85 | 0.52 | 0.05 | 0.67 | 0.68 | 0.23 | 0.19 | 0.09 |
| EPS Diluted | 1.35 | 1.02 | 0.74 | 0.11 | 0.78 | 0.52 | 0.04 | 0.60 | 0.60 | 0.20 | 0.19 | 0.09 |
| Weighted Avg Shares Out | 12.60M | 12.56M | 12.35M | 12.12M | 11.28M | 12.11M | 10.64M | 10.82M | 11.00M | 8.74M | 10.42M | 10.42M |
| Weighted Avg Shares Out (Dil) | 12.72M | 12.64M | 12.59M | 12.44M | 12.28M | 12.11M | 11.72M | 11.99M | 12.56M | 10.22M | 10.42M | 10.42M |
3 Top Profitable Stocks to Invest in Using Net Income Ratio
Perdoceo Education (PRDO), Boot Barn (BOOT) and iRadimed (IRMD) have been selected as the top picks with a high net income ratio.
Momentum Mondays: Stocks Setting up for an Epic Dip Buying Opportunity?
Want to start the week ahead of the pack? Check out ‘Momentum Mondays,' where I cover the leading breakout stocks in the market, summarize the major events of the week ahead, and prepare investors for profitable trading.
Time to Buy These Medical Stocks as Earnings Approach
Quarterly results from large retailers will highlight this week's earnings lineup but there are a few healthcare companies that investors will want to pay attention to as well.
iRadimed (IRMD) Is a Great Choice for 'Trend' Investors, Here's Why
iRadimed (IRMD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
IRadimed (IRMD) Q2 Earnings and Revenues Beat Estimates
IRadimed (IRMD) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.27 per share a year ago.
IRADIMED CORPORATION Announces Second Quarter 2023 Financial Results
WINTER SPRINGS, Fla., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced today its financial results for the three and six months ended June 30, 2023. The Company is a leader in the development of innovative magnetic...
IRADIMED CORPORATION to Hold 2023 Second Quarter Financial Results Conference Call on August 3rd
WINTER SPRINGS, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2023 second quarter financial results before the market opens on Thursday, August 3rd. Iradimed management will host a conference call...
2 Medical Stocks to Consider Buying in June
With solid top and bottom-line growth on the horizon for HealthEquity (HQY) and iRadimed (IRMD), they are starting to look like viable investments for 2023 and beyond.
iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable
iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Recent Price Trend in iRadimed (IRMD) is Your Friend, Here's Why
iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Source: https://incomestatements.info
Category: Stock Reports